Members News

01.07.2013bitop AG receives Frost & Sullivan’s 2013 New Product Innovation Award for its Ectoin® Allergy products
Frost & Sullivan, a global research organization of 1,800 analysts and consultants, monitors more than 300 industries and 250,000 companies to determine how best-in-class companies worldwide manage growth, innovation and leadership. Based on the findings of this research, Frost & Sullivan grants the 2013 European New Product Innovation Award in Extremolytes Therapeutics to bitop AG.

To determine the deserving recipient of the New Product Innovation Award, the following criteria were used to benchmark bitop AG's performance against key competitors:
• Innovative Element of the Product
• Leverage of Leading-Edge Technologies
• Value Added Features/Benefits
• Increased Customer ROI
• Customer Acquisition/Penetration Potential

The benchmark by Frost & Sullivan indicates that bitop AG has made available Ectoin®, one of the most commonly found extremolytes in nature, for human use. bitop AG has explored and validated Ectoin® as a naturally-derived ingredient to alleviate and treat symptoms of allergic diseases as allergic rhinitis or conjunctivitis. Additional benefits of Ectoin® can be achieved in the treatment of atopic dermatitis, dryness of the mucosa in the nose and of the conjunctiva in the eye while suffering from sicca syndromes and the reduction of common symptoms of cough and cold. All of bitop's Ectoin®-containing products are preservative-free and clinically tested. Therefore they satisfy end-consumer needs and fill an existing market niche.

Beyond that, Frost & Sullivan states that bitop AG has leveraged the use of Ectoin® in medical devices and cosmetics by developing an economically viable fermentation process that avoids human error and cross-contamination.
To strengthen its product line and to enable a stronger penetration of the market, bitop AG has put progressive research efforts into the exploration of using Ectoin® in alleviating symptoms of different diseases.

"This award for bitop AG emphasizes that our Ectoin®-containing medical devices fill a gap in the self-medication market " states Gregor K. Mirow, CEO of bitop AG. "The analysts at Frost & Sullivan have recognized that Ectoin® enables new and innovative treatment concepts for symptoms of typical self-medication diseases and that bitop AG successfully provides such clinically tested medical devices for the customers."